Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Vancouver, British Columbia--(Newsfile Corp
More than $2 billion in announced investments across at least ten major CDMOs is adding tens of thousands of liters of solid-phase peptide synthesis capacity in the United States, Europe, and Asia
TB-4: Clinical Data for Unrelated Endpoints Meaningful human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs) Clean Phase 1 safety Cosmetic dosing is extrapolated from these programs Note: Full-length trial data does not transfer to the TB-500 fragment, so verify vial identity
Ready when you are BPC-157 The body protection compound for accelerated healing From $169/mo compounded by a licensed 503A pharmacy, dispensed only after provider review
Research status in 2026 KPV is sold and studied as a research compound
US$ 26.07
:max_bytes(150000):strip_icc()/VWH-GettyImages-1807239973-944cddb21ce647c594217130457b8f00.jpg)
US$ 22.29
US$ 22.04
US$ 26.75
US$ 22.44
US$ 24.39
US$ 20.04
US$ 29.58
US$ 27.01
US$ 21.67
